Aventis Tripacel
Executive Summary
Diphtheria, tetanus and acellular pertussis vaccine will be reviewed Nov. 3 by FDA's Vaccines & Related Biological Products Advisory Committee. "The Pink Sheet" (Oct. 9, In Brief) misidentified the product trade name. The acellular pertussis component of Tripacel differs from the component in Aventis' marketed DTaP vaccine Tripedia. Aventis said it hopes Tripacel, under review at FDA, will provide the foundation for its future pediatric combination vaccines
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth